TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20204944
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of emotional disclosure and cognitive reappraisal (ED and COG)
Study: 16444855
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of L-arginine daily
Study: 16444855
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of L-arginine daily (Control)
Study: 16444855
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of L-arginine daily
Study: 16444855
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g of L-arginine daily
Study: 10534332
Drug: High-quality trials
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-quality trials sponsored by the drug and device industry
Study: 30657996
Drug: CL-108 (Hydrocodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CL-108 (Hydrocodone 7.5 mg/Acetaminophen 325 mg/Rapid-Release, Low-Dose Promethazine 12.5 mg)
Study: 30657996
Drug: Hydrocodone 7.5
Normalized name: HYDROCODONE 7.5/IBUPROFEN 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone 7.5 mg/Acetaminophen 325 mg (HC/APAP)
Study: 30400898
Drug: Self-testing (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-testing (oral testing)
Study: 30400898
Drug: Provider administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provider administered test (finger-prick testing)
Study: 30400898
Drug: Provider administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provider administered test (in-person counselling)
Study: 27085261
Drug: Treatment-experienced cohort
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-experienced cohort
Study: 22225858
Drug: Rivaroxaban with
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs)
Study: 22225858
Drug: Enoxaparin with
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs)
Study: 22225858
Drug: Rivaroxaban with
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban with concomitant use of platelet function inhibitors/acetylsalicylic acid
Study: 22225858
Drug: Enoxaparin with
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin with concomitant use of platelet function inhibitors/acetylsalicylic acid
Study: 15834592
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg with 1,000 mg calcium and 800 IU vitamin D daily
Study: 15834592
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg calcium and 800 IU vitamin D daily
Study: 10089855
Drug: Pacing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacing therapy
Study: 876327
Drug: Early systemic
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early systemic chemotherapy (5‐fluorouracil, cyclophosphamide and prednisone)
Study: 876327
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment upon appearance of progressive metastatic disease
Study: 876327
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment group (excluding early progression)
Study: 22730694
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment group
Study: 28587203
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA supplementation (520 mg of DHA + EPA-enriched fish-oil daily)
Study: 26158889
Drug: Guided Internet
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Internet Therapy (IT)
Study: 8018456
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (3 micrograms kg‐1 min‐1) with placebo
Study: 8018456
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (3 micrograms kg‐1 min‐1) with metoprolol
Study: 6233550
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler alone
Study: 2588205
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler plus spacer (slow inhaled flow rate, about 25 l/min)
Study: 2588205
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler plus spacer (fast inhaled flow rate, about 100 l/min)
Study: 2588205
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler plus spacer (slow inhaled flow rate)
Study: 2588205
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler plus spacer
Study: 796943
Drug: Ketoprofen (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (150 mg daily in three divided doses of 50 mg)
Study: 31428908
Drug: Lapatinib, trastuzumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib, trastuzumab, or the combination with chemotherapy
Study: 31428908
Drug: Dual HER2-targeted
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dual HER2-targeted therapy versus trastuzumab
Study: 28362143
Drug: Any combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any combination of foot alignments and/or hand constraints
Study: 14985220
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg daily for 2 weeks)
Study: 11341459
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment after trial
Study: 9145841
Drug: Ritonavir 200
Normalized name: lopinavir-ritonavir 200 mg-50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 200 mg every 12 h for 2 weeks
Study: 9145841
Drug: Ritonavir 300
Normalized name: nirmatrelvir / ritonavir 300 MG /100 MG ; 150 MG / 100 MG Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 300 mg every 12 h for 2 weeks
Study: 9145841
Drug: Ritonavir 400
Normalized name: lopinavir-ritonavir 400 mg-100 mg/5 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 400 mg every 12 h for 2 weeks
Study: 9145841
Drug: Ritonavir 500
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir 500 mg every 12 h for 2 weeks
Study: 27401788
Drug: Cilostazol 200
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 200 mg/d for 12 weeks
Study: 23733798
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of zinc orally every day for 2 weeks
Study: 23733798
Drug: Placebo suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suspension orally every day for 2 weeks
Study: 19266828
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 microg kg(‐1) as preinduction over 15 min and 0.2‐1 microg kg(‐1) hr(‐1) by continuous i.v. infusion during operation
Study: 17290160
Drug: Isoflavones (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavones (60 mg daily for 3 months)
Study: 2713513
Drug: Induction chemotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy, adjusted loco-regional treatment (surgery and/or radiotherapy) and adjuvant chemotherapy with or without immunostimulation
Study: 1094562
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clofibrate and cholestyramine
Study: 17852628
Drug: 1072 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1072 nm light treatment for a period of between 6 and 8 weeks
Study: 11679859
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg prochlorperazine administered intravenously by means of 2‐minute push (bolus group)
Study: 11679859
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg prochlorperazine diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15‐minute period (infusion group)
Study: 9175991
Drug: Low-sodium diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium diet (mean urinary Na excretion 61 mmol/24 h)
Study: 9175991
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (mean urinary Na excretion 142 mmol/24 h)
Study: 8200248
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (Lupron Depot 3.75 mg for one month, then daily subcutaneous dose increased from 0.5 mg to 1.0-1.5 mg)
Study: 8200248
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (maximum therapeutic dosage)
Study: 2828072
Drug: High-dose etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose etoposide (350 mg/m2/day for 5 days) and cisplatin (40 mg/m2/day for 5 days)
Study: 2828072
Drug: High-dose etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose etoposide (350 mg/m2/day for 5 days)
Study: 21898419
Drug: Medialization laryngoplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medialization laryngoplasty (ML)
Study: 16960414
Drug: Lidocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1 mg kg(‐1) IV)
Study: 15082207
Drug: Vardenafil 10mg
Normalized name: vardenafil 10 MG
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vardenafil 10mg (flexible dosing allowed: 5mg, 10mg, or 20mg)
Study: 11174341
Drug: Milrinone bolus
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone bolus followed by continuous infusion (n = 9)
Study: 11174341
Drug: Placebo bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bolus followed by continuous milrinone infusion (n = 10)
Study: 9508162
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality treatment (CT + RT)
Study: 8165955
Drug: New Marburg
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Marburg rehabilitation concept (group A) - additional twice a week exercise in a fitness center under medical supervision
Study: 3073463
Drug: Urokinase (small
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase (small repeated doses)
Study: 3073463
Drug: Urokinase (large
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase (large single dose)
Study: 3073463
Drug: Urokinase and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase and Heparin
Study: 30879076
Drug: Higher dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dialysis dose (spKt/Vurea 1.7)
Study: 31335651
Drug: Pregabalin (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (titrated to maximum dose 600 mg per day)
Study: 26625980
Drug: mHealth assisted
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth assisted healthy lifestyle intervention package including motivational counseling, low GI nutritional advice, daily physical activity prescription, and smartphone app support
Study: 24448262
Drug: Topical tetracycline
Normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracycline for children younger than 6 months and oral azithromycin for those 6 months and older (annual MDA)
Study: 22241792
Drug: Single-agent lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-agent lenalidomide with pneumococcal 7-valent conjugate vaccine (PCV) in Cohort B (both vaccinations while on lenalidomide)
Study: 22241792
Drug: Single-agent lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-agent lenalidomide with pneumococcal 7-valent conjugate vaccine (PCV) in Cohort A (first vaccination prior to lenalidomide, second while on lenalidomide)
Study: 15521079
Drug: 3000 ml
Normalized name: TPN Bag 3000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 ml normal saline intravenously for 24 h before drainage
Study: 15521079
Drug: No saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: No saline infusion (control group)
Study: 11981147
Drug: Clevidipine (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevidipine (doses greater than or equal to 1.37 microg.kg-1.min-1)
Study: 7884257
Drug: Allopurinol (100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (100-300 mg/day for seven days before operation)
Study: 2224784
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy regimen A1 (cyclophosphamide 1200 mg/m2, vincristine 1.5 mg/m2, pyrarubicin 40 mg/m2, cisplatin 90 mg/m2) followed by bone marrow transplantation (BMT)
Study: 2224784
Drug: Alternating treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating treatment by regimen B (cyclophosphamide and ACNU) and intensified regimen A1
Study: 2224784
Drug: Alternating administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alternating administration of regimen C (cyclophosphamide and DTIC) and intensified A1
Study: 534065
Drug: 30% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% urea (intravenous)
Study: 534065
Drug: 20% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% mannitol (intravenous)
Study: 534065
Drug: 30% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% urea (oral)
Study: 534065
Drug: 10% glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glycerol (oral)
Study: 534065
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of thiopental (in conjunction with hyperosmotic agents)
Study: 29020293
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with darunavir/ritonavir and lamivudine
Study: 29020293
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with darunavir/ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine
Study: 26169691
Drug: 532-nm Q-switched
Normalized name: Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: 532-nm Q-switched Nd:YAG laser treatment
Study: 23427000
Drug: GS-9667 (30-1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9667 (30-1,800 mg single dose)
Study: 23427000
Drug: GS-9667 (600-2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9667 (600-2,400 mg QD, 1,200 mg BID, or 600 mg QID for 14 days)
Study: 21111684
Drug: Escalating Dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating Dose
Study: 21111684
Drug: Stable Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable Dose
Study: 9136940
Drug: Interferon alpha‐2A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha‐2A (Roferon‐A) as a co‐induction agent with intensive combination chemotherapy (PCAB: prednisone 60 mg/m2 days 1‐5, cyclophosphamide 600 mg/m2 day 1, BCNU 30 mg/m2 day 1, doxorubicin 30 mg/m2 day 1, repeated every 28 d for a total of 12 cycles)
Study: 9136940
Drug: Intensive combination
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive combination chemotherapy (PCAB) without interferon
Study: 8201815
Drug: Video projection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video projection of humorous movies four times daily for 3 months
Study: 3720035
Drug: Intensive dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive dialysis (maintaining predialysis blood urea nitrogen below 60 mg/dl and serum creatinine below 5 mg/dl)
Study: 3720035
Drug: Non-intensive dialysis
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-intensive dialysis (maintaining predialysis blood urea nitrogen below 100 mg/dl and serum creatinine below 9 mg/dl)
Study: 28551715
Drug: Modafinil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (600 mg)
Study: 25004111
Drug: Venom Immunotherapy
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venom Immunotherapy (VIT) for 4 months
Study: 7762912
Drug: Heparin at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin at a bolus dose of 2000 U at the initiation of dialysis followed by 1000 U/h during 4-hour hemodialysis sessions
Study: 2407002
Drug: Euro-Collins solution
Normalized name: Collinsonia extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euro-Collins solution
Study: 7428411
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg naproxen, 400 mg ibuprofen, and 25 mg indomethacin twice daily with 500 mg naproxen suppository at night
Study: 7428411
Drug: Naproxen tablet
Normalized name: Naproxen Tablets
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen tablet and suppository phase
Study: 7428411
Drug: Indomethacin capsule
Normalized name: Indomethacin Capsules
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin capsule and naproxen suppository phase
Study: 7428411
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of two non-steroidal anti-inflammatory drugs
Study: 25306870
Drug: RetinSphere (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: RetinSphere (topical retinoid combination)
Study: 22167112
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of nicotine replacement therapy (NRT; nicotine patch) + 6 sessions of motivational interviewing (MI)
Study: 22167112
Drug: NRT (nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRT (nicotine patch)
Study: 14578869
Drug: Recombinant HCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant HCV E1 (20 mug) administered intramuscularly at weeks 0, 4, 8, 12, and 24.
Study: 14578869
Drug: Placebo (alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (alum only) administered intramuscularly at weeks 0, 4, 8, 12, and 24.
Study: 10714552
Drug: G-CSF from
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF from day 0 to day 13 after HDCT (arm A)
Study: 10714552
Drug: G-CSF from
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF from day 0 to day 6 and GM-CSF from day 7 to day 13 (arm B)
Study: 3899368
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Nimodipine
Study: 31619305
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment (specific antipsychotics not detailed) over an 18-month period
Study: 29278718
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Therapy for Obesity (CRT-O)
Study: 25800045
Drug: Topical Citrullus
Normalized name: Citrullus colocynthis fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Citrullus colocynthis extract oil
Study: 22781295
Drug: LACJ therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LACJ therapy (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg + Jinghuaweikang 3 capsules)
Study: 22781295
Drug: LACB therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LACB therapy (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg + bismuth potassium citrate 220 mg)
Study: 22781295
Drug: LAC therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC therapy (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg)
Study: 22781295
Drug: LACJ therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LACJ therapy
Study: 22781295
Drug: LACB therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LACB therapy
Study: 22781295
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of antibiotic-resistant genes
Study: 8894500
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg NN623
Study: 8894500
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg A4166
Study: 8894500
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg NN623
Study: 6804161
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives with 50 micrograms or less of ethinyl estradiol
Study: 6804161
Drug: Preparation containing
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation containing 20 micrograms ethinyl estradiol
Study: 6804161
Drug: Preparation containing
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation containing 400 micrograms norethisterone acetate
Study: 6804161
Drug: Norethisterone preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone preparations
Study: 6804161
Drug: Levonorgestrel-containing preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel-containing preparations